Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia

Neurobiology of Disease

Volumn 71, Issue , 2014, Pages 245-259

  Hulse, R P ^a,e   Beazley Long, N ^a,e   Hua, J ^a   Kennedy, H ^a   Prager, J ^a   Bevan, H ^a   Qiu, Y ^a   Fernandes, E S ^b   Gammons, M V ^a   Ballmer Hofer, K ^c   Gittenberger de Groot, A C ^d   Churchill, A J ^a   Harper, S J ^a   Brain, S D ^b   Bates, D O ^e   Donaldson, L F ^a,e  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Alternative mRNA splicing; Neuropathy; Nociceptors; Vascular endothelial growth factor A

Indexed keywords

(3AS,4S,9BS)-N-(2-(8-CYANO-1-FORMYL-2,3,3A,4,5,9B-HEXAHYDRO-1H-PYRROLO(3,2-C)QUINOLIN-4-YL)-2-METHYLPROPYL)-4,6-DIFLUOROBENZOFURAN-2-CARBOXYAMIDE; ANTIBODY; BENZOFURAN DERIVATIVE; ENZYME INHIBITOR; MESSENGER RNA; QUINOLINE DERIVATIVE; RECOMBINANT DNA; TRPV1 PROTEIN, MOUSE; VANILLOID RECEPTOR; VASCULOTROPIN A;

ANIMAL; CYTOLOGY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HYPERALGESIA; IMMUNOLOGY; MALE; METABOLISM; MOUSE; NERVE CONDUCTION; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; PHYSIOLOGY; RAT; SENSORY NERVE CELL; SPINAL GANGLION; TRANSGENIC MOUSE; WISTAR RAT;

ANIMALS; ANTIBODIES; BENZOFURANS; DISEASE MODELS, ANIMAL; DNA, RECOMBINANT; ENZYME INHIBITORS; GANGLIA, SPINAL; HYPERALGESIA; MALE; MICE; MICE, TRANSGENIC; NEURAL CONDUCTION; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; QUINOLINES; RATS; RATS, WISTAR; RNA, MESSENGER; SENSORY RECEPTOR CELLS; TRPV CATION CHANNELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84949115606     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.08.012     Document Type: Article

References (119)

1. Akopian A.N. Regulation of nociceptive transmission at the periphery via TRPA1-TRPV1 interactions. Curr. Pharm. Biotechnol. 2011, 12:89-94.
2. Amin E.M., et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 2011, 20:768-780.
3. Amiri S., et al. Differential gene expression and alternative splicing of survivin following mouse sciatic nerve injury. Spinal Cord 2009, 47:739-744.
4. Anczukow O., et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat. Struct. Mol. Biol. 2012, 19:220-228.
5. Aubol B.E., Adams J.A. Applying the brakes to multisite SR protein phosphorylation: substrate-induced effects on the splicing kinase SRPK1. Biochemistry 2011, 50:6888-6900.
6. Ballmer-Hofer K., et al. Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood 2011, 118:816-826.
7. Bates D.O., et al. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin. Cancer Res. 2012, 18:6384-6391.
8. Bates D.O., et al. Detection of VEGF-Axxxb isoforms in human tissues. PLoS ONE 2013, 8:e68399.
9. Beazley-Long N., et al. VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor a in vivo and in vitro. Am. J. Pathol. 2013, 183:918-929.
10. Benton R.L., Whittemore S.R. VEGF165 therapy exacerbates secondary damage following spinal cord injury. Neurochem. Res. 2003, 28:1693-1703.
11. Brenneis C., et al. Phenotyping the function of TRPV1-expressing sensory neurons by targeted axonal silencing. J. Neurosci. 2013, 33:315-326.
12. Burger R.A., et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2007, 25:5165-5171.
13. Caterina M.J., et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
14. Caterina M.J., et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000, 288:306-313.
15. Cebe Suarez S., et al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell. Mol. Life Sci. 2006, 63:2067-2077.
16. Chen W., et al. Immortalization and characterization of a nociceptive dorsal root ganglion sensory neuronal line. J. Peripher. Nerv. Syst. 2007, 12:121-130.
17. Chen J., et al. Expression patterns in alternative splicing forms of prosaposin mRNA in the rat facial nerve nucleus after facial nerve transection. Neurosci. Res. 2008, 60:82-94.
18. Chen X., et al. Does the anti-hyperalgesic disruptor of endothelial cells, octoxynol-9, alter nociceptor function?. J. Neurophysiol. 2014, 112(2):463-466. 10.1152/jn.00034.2014.
19. Cohen D.J., Hochster H.S. Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer. Clin. Colorectal Cancer 2007, 7(Suppl. 1):S21-S27.
20. Cohen M.H., et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007, 12:713-718.
21. Das S., et al. Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep. 2012, 1:110-117.
22. Dina O.A., et al. Integrin signaling in inflammatory and neuropathic pain in the rat. Eur. J. Neurosci. 2004, 19:634-642.
23. Djouhri L., et al. Spontaneous pain, both neuropathic and inflammatory, is related to frequency of spontaneous firing in intact C-fiber nociceptors. J. Neurosci. 2006, 26:1281-1292.
24. Djouhri L., et al. Partial nerve injury induces electrophysiological changes in conducting (uninjured) nociceptive and nonnociceptive DRG neurons: possible relationships to aspects of peripheral neuropathic pain and paresthesias. Pain 2012, 153:1824-1836.
25. Donaldson L.F. Unilateral arthritis: contralateral effects. Trends Neurosci. 1999, 22:495-496.
26. Dunham J. On the role of TRPA1 in acute and inflammatory nociception. Physiology and Pharmacology 2008, 244. PhD. University of Bristol, Bristol.
27. Dunham J.P., et al. Inflammation reduces mechanical thresholds in a population of transient receptor potential channel A1-expressing nociceptors in the rat. Eur. J. Neurosci. 2008, 27:3151-3160.
28. Edmond V., et al. SRSF2 is required for sodium butyrate-mediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines. Cell Cycle 2011, 10:1968-1977.
29. Fang X., et al. trkA is expressed in nociceptive neurons and influences electrophysiological properties via Nav1.8 expression in rapidly conducting nociceptors. J. Neurosci. 2005, 25:4868-4878.
30. Fang X., et al. Intense isolectin-B4 binding in rat dorsal root ganglion neurons distinguishes C-fiber nociceptors with broad action potentials and high Nav1.9 expression. J. Neurosci. 2006, 26:7281-7292.
31. Fernandes E.S., et al. A distinct role for transient receptor potential ankyrin 1, in addition to transient receptor potential vanilloid 1, in tumor necrosis factor alpha-induced inflammatory hyperalgesia and Freund's complete adjuvant-induced monarthritis. Arthritis Rheum. 2011, 63:819-829.
32. Fernandes E.S., et al. The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br. J. Pharmacol. 2012, 166:510-521.
33. Fernandes E.S., et al. Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B4-induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1. Faseb J. 2013, 27(4):1664-1673.
34. Ferrari L.F., et al. Nociceptor subpopulations involved in hyperalgesic priming. Neuroscience 2010, 165:896-901.
35. Fluhr K., et al. Capsaicin or menthol sensitization induces quantitative but no qualitative changes to thermal and mechanical pain thresholds. Clin. J. Pain 2009, 25:128-131.
36. Fukuhara T., et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11329-11333.
37. Gammons M.V., et al. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2013, 54:5797-5806.
38. Garcia A.A., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol. 2008, 26:76-82.
39. Ghigna C., et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol. Cell 2005, 20:881-890.
40. Ghosh G., Adams J.A. Phosphorylation mechanism and structure of serine-arginine protein kinases. FEBS J. 2011, 278:587-597.
41. Giannakouros T., et al. Serine-arginine protein kinases: a small protein kinase family with a large cellular presence. FEBS J. 2011, 278:570-586.
42. Grosios K., et al. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm. Res. 2004, 53:133-142.
43. Grubb B.D. Peripheral and central mechanisms of pain. Br. J. Anaesth. 1998, 81:8-11.
44. Hargreaves K., et al. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88.
45. Harper S.J., Bates D.O. VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat. Rev. Cancer 2008, 8:880-887.
46. Harris S., et al. Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale. PLoS ONE 2012, 7:e35231.
47. Herrera J.J., et al. Reduced vascular endothelial growth factor expression in contusive spinal cord injury. J. Neurotrauma 2009, 26:995-1003.
48. Hoffmann T., et al. Projected pain from noxious heat stimulation of an exposed peripheral nerve - a case report. Eur. J. Pain 2009, 13:35-37.
49. Hua J., et al. Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2010, 51:4282-4288.
50. Hulse R., et al. Characterization of a novel neuropathic pain model in mice. Neuroreport 2008, 19:825-829.
51. Hulse R., et al. Block of VEGF receptor 2 causes mechanical allodynia and peripheral sensitisation of mechanonociceptors in vivo. 13th World Congress on Pain International Association for the Study of Pain (IASP), Montreal, Canada 2010, PM280.
52. Hulse R., et al. Intact cutaneous C fibre afferent properties in mechanical and cold neuropathic allodynia. Eur. J. Pain 2010, 14. (565 e1-565 e10).
53. Hulse R.P., et al. Vascular endothelial growth factor splice variants VEGF165a and VEGF165b modulate spinal nociceptive processing in the rat. Physiology 2012, PC263. Proc Physiol Soc, Edinburgh.
54. Jones R.C., et al. The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3. J. Neurosci. 2005, 25:10981-10989.
55. Joseph E.K., et al. PLC-beta 3 signals upstream of PKC epsilon in acute and chronic inflammatory hyperalgesia. Pain 2007, 132:67-73.
56. Joseph E.K., et al. Vascular endothelial cells mediate mechanical stimulation-induced enhancement of endothelin hyperalgesia via activation of P2X2/3 receptors on nociceptors. J. Neurosci. 2013, 33:2849-2859.
57. Joseph E.K., et al. ATP release mechanisms of endothelial cell-mediated stimulus-dependent hyperalgesia. J Pain 2014, 15(7):771-777.
58. Karni R., et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 2007, 14:185-193.
59. Kawamura H., et al. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res. 2008, 68:4683-4692.
60. Kelly S., et al. Increased function of pronociceptive TRPV1 at the level of the joint in a rat model of osteoarthritis pain. Ann. Rheum. Dis. 2013, 10.1136/annrheumdis-2013-203413.
61. Kerber G., et al. Neuregulin-1 isoforms are differentially expressed in the intact and regenerating adult rat nervous system. J. Mol. Neurosci. 2003, 21:149-165.
62. Kerr N., et al. The expression of ELK transcription factors in adult DRG: Novel isoforms, antisense transcripts and upregulation by nerve damage. Mol. Cell. Neurosci. 2010, 44:165-177.
63. Kiryu-Seo S., et al. A sequence-specific splicing activator, tra2beta, is up-regulated in response to nerve injury. Brain Res. Mol. Brain Res. 1998, 62:220-223.
64. Kisko K., et al. Structural analysis of vascular endothelial growth factor receptor-2/ligand complexes by small-angle X-ray solution scattering. Faseb J. 2011, 25:2980-2986.
65. Kiyatkin M.E., et al. Combined genetic and pharmacological inhibition of TRPV1 and P2X3 attenuates colorectal hypersensitivity and afferent sensitization. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305:G638-G648.
66. Koltzenburg M., et al. Neutralization of endogenous NGF prevents the sensitization of nociceptors supplying inflamed skin. Eur. J. Neurosci. 1999, 11:1698-1704.
67. Koltzenburg M., et al. Does the right side know what the left is doing?. Trends Neurosci. 1999, 22:122-127.
68. Lam D.K., et al. Glutamate and capsaicin effects on trigeminal nociception I: activation and peripheral sensitization of deep craniofacial nociceptive afferents. Brain Res. 2009, 1251:130-139.
69. Lambert R. Breeding strategies for maintaining colonies of laboratory mice 2009, A Jackson Laboratory Resource Manual, The Jackson Laboratory.
70. Langenberg M.H., et al. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Ann. Oncol. 2011, 10.1093/annonc/mdq767.
71. Lennertz R.C., et al. TRPA1 mediates mechanical sensitization in nociceptors during inflammation. PLoS ONE 2012, 7:e43597.
72. Levine J.D., Alessandri-Haber N. TRP channels: targets for the relief of pain. Biochim. Biophys. Acta 2007, 1772:989-1003.
73. Li D., et al. Sensitization of primary afferent nociceptors induced by intradermal capsaicin involves the peripheral release of calcitonin gene-related peptide driven by dorsal root reflexes. J Pain. 2008, 9:1155-1168.
74. Liang W.C., et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 2006, 281:951-961.
75. Lin J., et al. VEGF and its receptor-2 involved in neuropathic pain transmission mediated by P2X(2)(/)(3) receptor of primary sensory neurons. Brain Res. Bull. 2010, 83:284-291.
76. Liu S., et al. Vatalanib decrease the positive interaction of VEGF receptor-2 and P2X2/3 receptor in chronic constriction injury rats. Neurochem. Int. 2012, 60:565-572.
77. Lynn B., Carpenter S.E. Primary afferent units from the hairy skin of the rat hind limb. Brain Res. 1982, 238:29-43.
78. Malykhina A.P., et al. VEGF induces sensory and motor peripheral plasticity, alters bladder function, and promotes visceral sensitivity. BMC Physiol. 2012, 12:15.
79. Mei S., et al. Mechanisms underlying somatostatin receptor 2 down-regulation of vascular endothelial growth factor expression in response to hypoxia in mouse retinal explants. J. Pathol. 2012, 226:519-533.
80. Miller K., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357:2666-2676.
81. Moriyama T., et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol. Pain 2005, 1:3.
82. Nesic O., et al. Vascular endothelial growth factor and spinal cord injury pain. J. Neurotrauma 2010, 27:1793-1803.
83. Ngo J.C., et al. Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol. Cell 2005, 20:77-89.
84. Nowak D.G., et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J. Cell Sci. 2008, 121:3487-3495.
85. Nowak D.G., et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J. Biol. Chem. 2010, 285:5532-5540.
86. Obata K., et al. Contribution of degeneration of motor and sensory fibers to pain behavior and the changes in neurotrophic factors in rat dorsal root ganglion. Exp. Neurol. 2004, 188:149-160.
87. Pan H.L., et al. Modulation of pain transmission by G-protein-coupled receptors. Pharmacol. Ther. 2008, 117:141-161.
88. Papoutsopoulou S., et al. SRPK1 and LBR protein kinases show identical substrate specificities. Biochem. Biophys. Res. Commun. 1999, 255:602-607.
89. Pritchard-Jones R.O., et al. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br. J. Cancer 2007, 97:223-230.
90. Raouf R., et al. Sodium channels and mammalian sensory mechanotransduction. Mol. Pain 2012, 8:21.
91. Ravnefjord A., et al. Involvement of the transient receptor potential vanilloid 1 (TRPV1) in the development of acute visceral hyperalgesia during colorectal distension in rats. Eur. J. Pharmacol. 2009, 611:85-91.
92. Ren Y., et al. Sympathetic modulation of activity in Adelta- and C-primary nociceptive afferents after intradermal injection of capsaicin in rats. J. Neurophysiol. 2005, 93:365-377.
93. Ren Y., et al. Involvement of peripheral purinoceptors in sympathetic modulation of capsaicin-induced sensitization of primary afferent fibers. J. Neurophysiol. 2006, 96:2207-2216.
94. Rice A.S., et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2014, 383:1637-1647.
95. Ristoiu V., et al. Hypoxia-induced sensitization of transient receptor potential vanilloid 1 involves activation of hypoxia-inducible factor-1 alpha and PKC. Pain 2011, 152:936-945.
96. Rosenbaum T., Simon S.A. TRPV1 receptors and signal transduction. TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades 2007, CRC Press. W.B. Liedtke, H. S (Eds.).
97. Rosenstein J.M., Krum J.M. New roles for VEGF in nervous tissue - beyond blood vessels. Exp. Neurol. 2004, 187:246-253.
98. Shim B., et al. Mechanical and heat sensitization of cutaneous nociceptors in rats with experimental peripheral neuropathy. Neuroscience 2005, 132:193-201.
99. Sondell M., et al. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur. J. Neurosci. 2000, 12:4243-4254.
100. Stamboulian S., et al. ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating properties. J. Neurosci. 2010, 30:1637-1647.
101. Storkebaum E., et al. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004, 26:943-954.
102. Sundberg L.M., et al. Effect of vascular endothelial growth factor treatment in experimental traumatic spinal cord injury: in vivo longitudinal assessment. J. Neurotrauma 2011, 28(4):565-578. 10.1089/neu.2010.1533.
103. Teng A.C., et al. IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression. Faseb J. 2010, 24:4825-4834.
104. Thorsen K., et al. Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. Mol. Cell. Proteomics 2011, 10(M110):002998.
105. Varga A., et al. Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat. Neurosci. Lett. 2005, 385:137-142.
106. Velazquez-Dones A., et al. Mass spectrometric and kinetic analysis of ASF/SF2 phosphorylation by SRPK1 and Clk/Sty. J. Biol. Chem. 2005, 280:41761-41768.
107. Verheyen A., et al. Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. Brain 2012, 135:2629-2641.
108. Verheyen A., et al. Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies. Neuroscience 2013, 244:77-89.
109. Walczak J.S., et al. Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 2005, 132:1093-1102.
110. Wang J., et al. Octreotide inhibits capsaicin-induced activation of C and Adelta afferent fibres in rat hairy skin in vivo. Clin. Exp. Pharmacol. Physiol. 2011, 38:521-527.
111. Whittles C.E., et al. ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation 2002, 9:513-522.
112. Wilkinson-Berka J.L. Diabetes and retinal vascular disorders: role of the renin-angiotensin system. Expert Rev. Mol. Med. 2004, 6:1-18.
113. Wong L.F., et al. Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord. Nat. Neurosci. 2006, 9:243-250.
114. Wood J.M., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60:2178-2189.
115. Woolard J., et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004, 64:7822-7835.
116. Yamamizu K., et al. The kappa opioid system regulates endothelial cell differentiation and pathfinding in vascular development. Blood 2011, 118:775-785.
117. Yamamizu K., et al. small ka, Cyrillic Opioids inhibit tumor angiogenesis by suppressing VEGF signaling. Sci. Rep. 2013, 3, 3213.
118. Zheng C., et al. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochem. Biophys. Res. Commun. 2007, 363:989-993.
119. Zhou Z., et al. The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol. Cell 2012, 47:422-433.